Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 14/20 | 0.48 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.38 |
| ▸ | RET | P07949 | 2/20 | 0.36 |
| ▸ | KIF11 | P52732 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20150749 | 0.86 | PDE2A (0.52) | PDE2APTGDR2 | |
| SCHEMBL18291814 | 0.85 | PDE2A (0.52) | PDE2AALDH1A1 | |
| SCHEMBL20150745 | 0.83 | PDE2A (0.46) | PDE2APTGDR2RETALDH1A1 | |
| SCHEMBL20150746 | 0.83 | PDE2A (0.49) | PDE2AALDH1A1 | |
| SCHEMBL20138450 | 0.83 | PDE2A (0.71) | PDE2ARET | |
| SCHEMBL20150751 | 0.83 | PDE2A (0.46) | PDE2APTGDR2RETALDH1A1 | |
| SCHEMBL20150753 | 0.80 | PDE2A (0.46) | PDE2APTGDR2RETALDH1A1 | |
| SCHEMBL20150742 | 0.80 | PDE2A (0.72) | PDE2A | |
| SCHEMBL20150747 | 0.80 | PDE2A (0.46) | PDE2ARET | |
| SCHEMBL20150756 | 0.78 | PDE2A (0.50) | PDE2APTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180134712-A1 | 6-ALKYL DIHYDROPYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134712-A1 | 6-ALKYL DIHYDROPYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | PDE12, PDE2A, PDE4D | PDE2A 2/4885PTGDR2 93/4885RET 2086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.